Global Sexual Dysfunction Drugs Market Research Report 2021

1 Sexual Dysfunction Drugs Market Overview

• 1.1 Product Overview and Scope of Sexual Dysfunction Drugs
• 1.2 Sexual Dysfunction Drugs Segment by Type
  • 1.2.1 Global Sexual Dysfunction Drugs Sales Growth Rate Comparison by Type (2021-2027)
  • 1.2.2 Oral Therapy
  • 1.2.3 Intracavernosal Therapy
  • 1.2.4 Hormonal Therapy
  • 1.2.5 Transurethral Therapy
• 1.3 Sexual Dysfunction Drugs Segment by Application
  • 1.3.1 Sexual Dysfunction Drugs Sales Comparison by Application: (2021-2027)
  • 1.3.2 Male
  • 1.3.3 Female
• 1.4 Global Sexual Dysfunction Drugs Market Size Estimates and Forecasts
  • 1.4.1 Global Sexual Dysfunction Drugs Revenue 2016-2027
  • 1.4.2 Global Sexual Dysfunction Drugs Sales 2016-2027
  • 1.4.3 Sexual Dysfunction Drugs Market Size by Region: 2016 Versus 2021 Versus 2027

2 Sexual Dysfunction Drugs Market Competition by Manufacturers

• 2.1 Global Sexual Dysfunction Drugs Sales Market Share by Manufacturers (2016-2021)
• 2.2 Global Sexual Dysfunction Drugs Revenue Market Share by Manufacturers (2016-2021)
• 2.3 Global Sexual Dysfunction Drugs Average Price by Manufacturers (2016-2021)
• 2.4 Manufacturers Sexual Dysfunction Drugs Manufacturing Sites, Area Served, Product Type
• 2.5 Sexual Dysfunction Drugs Market Competitive Situation and Trends
  • 2.5.1 Sexual Dysfunction Drugs Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest Sexual Dysfunction Drugs Players Market Share by Revenue
  • 2.5.3 Global Sexual Dysfunction Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Sexual Dysfunction Drugs Retrospective Market Scenario by Region

• 3.1 Global Sexual Dysfunction Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
• 3.2 Global Sexual Dysfunction Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
• 3.3 North America Sexual Dysfunction Drugs Market Facts & Figures by Country
  • 3.3.1 North America Sexual Dysfunction Drugs Sales by Country
  • 3.3.2 North America Sexual Dysfunction Drugs Revenue by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe Sexual Dysfunction Drugs Market Facts & Figures by Country
  • 3.4.1 Europe Sexual Dysfunction Drugs Sales by Country
  • 3.4.2 Europe Sexual Dysfunction Drugs Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific Sexual Dysfunction Drugs Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Sexual Dysfunction Drugs Sales by Region
  • 3.5.2 Asia Pacific Sexual Dysfunction Drugs Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America Sexual Dysfunction Drugs Market Facts & Figures by Country
  • 3.6.1 Latin America Sexual Dysfunction Drugs Sales by Country
  • 3.6.2 Latin America Sexual Dysfunction Drugs Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
• 3.7 Middle East and Africa Sexual Dysfunction Drugs Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Sexual Dysfunction Drugs Sales by Country
  • 3.7.2 Middle East and Africa Sexual Dysfunction Drugs Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 U.A.E

4 Global Sexual Dysfunction Drugs Historic Market Analysis by Type

• 4.1 Global Sexual Dysfunction Drugs Sales Market Share by Type (2016-2021)
• 4.2 Global Sexual Dysfunction Drugs Revenue Market Share by Type (2016-2021)
• 4.3 Global Sexual Dysfunction Drugs Price by Type (2016-2021)

5 Global Sexual Dysfunction Drugs Historic Market Analysis by Application

• 5.1 Global Sexual Dysfunction Drugs Sales Market Share by Application (2016-2021)
• 5.2 Global Sexual Dysfunction Drugs Revenue Market Share by Application (2016-2021)
• 5.3 Global Sexual Dysfunction Drugs Price by Application (2016-2021)

6 Key Companies Profiled

• 6.1 Pfizer
  • 6.1.1 Pfizer Corporation Information
  • 6.1.2 Pfizer Description and Business Overview
  • 6.1.3 Pfizer Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 6.1.4 Pfizer Product Portfolio
  • 6.1.5 Pfizer Recent Developments/Updates
• 6.2 GlaxoSmithKline
  • 6.2.1 GlaxoSmithKline Corporation Information
  • 6.2.2 GlaxoSmithKline Description and Business Overview
  • 6.2.3 GlaxoSmithKline Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 6.2.4 GlaxoSmithKline Product Portfolio
  • 6.2.5 GlaxoSmithKline Recent Developments/Updates
• 6.3 Merck
  • 6.3.1 Merck Corporation Information
  • 6.3.2 Merck Description and Business Overview
  • 6.3.3 Merck Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 6.3.4 Merck Product Portfolio
  • 6.3.5 Merck Recent Developments/Updates
• 6.4 Eli Lilly
  • 6.4.1 Eli Lilly Corporation Information
  • 6.4.2 Eli Lilly Description and Business Overview
  • 6.4.3 Eli Lilly Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Eli Lilly Product Portfolio
  • 6.4.5 Eli Lilly Recent Developments/Updates
• 6.5 AbbVie
  • 6.5.1 AbbVie Corporation Information
  • 6.5.2 AbbVie Description and Business Overview
  • 6.5.3 AbbVie Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 6.5.4 AbbVie Product Portfolio
  • 6.5.5 AbbVie Recent Developments/Updates
• 6.6 Bayer
  • 6.6.1 Bayer Corporation Information
  • 6.6.2 Bayer Description and Business Overview
  • 6.6.3 Bayer Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 6.6.4 Bayer Product Portfolio
  • 6.6.5 Bayer Recent Developments/Updates
• 6.7 Teva Pharmaceutical Industries
  • 6.6.1 Teva Pharmaceutical Industries Corporation Information
  • 6.6.2 Teva Pharmaceutical Industries Description and Business Overview
  • 6.6.3 Teva Pharmaceutical Industries Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Teva Pharmaceutical Industries Product Portfolio
  • 6.7.5 Teva Pharmaceutical Industries Recent Developments/Updates
• 6.8 Takeda
  • 6.8.1 Takeda Corporation Information
  • 6.8.2 Takeda Description and Business Overview
  • 6.8.3 Takeda Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 6.8.4 Takeda Product Portfolio
  • 6.8.5 Takeda Recent Developments/Updates
• 6.9 Apricus Biosciences
  • 6.9.1 Apricus Biosciences Corporation Information
  • 6.9.2 Apricus Biosciences Description and Business Overview
  • 6.9.3 Apricus Biosciences Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 6.9.4 Apricus Biosciences Product Portfolio
  • 6.9.5 Apricus Biosciences Recent Developments/Updates
• 6.10 Emotional Brain
  • 6.10.1 Emotional Brain Corporation Information
  • 6.10.2 Emotional Brain Description and Business Overview
  • 6.10.3 Emotional Brain Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 6.10.4 Emotional Brain Product Portfolio
  • 6.10.5 Emotional Brain Recent Developments/Updates
• 6.11 Ivix LLX
  • 6.11.1 Ivix LLX Corporation Information
  • 6.11.2 Ivix LLX Sexual Dysfunction Drugs Description and Business Overview
  • 6.11.3 Ivix LLX Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 6.11.4 Ivix LLX Product Portfolio
  • 6.11.5 Ivix LLX Recent Developments/Updates
• 6.12 Leadiant Biosciences
  • 6.12.1 Leadiant Biosciences Corporation Information
  • 6.12.2 Leadiant Biosciences Sexual Dysfunction Drugs Description and Business Overview
  • 6.12.3 Leadiant Biosciences Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 6.12.4 Leadiant Biosciences Product Portfolio
  • 6.12.5 Leadiant Biosciences Recent Developments/Updates
• 6.13 NexMed
  • 6.13.1 NexMed Corporation Information
  • 6.13.2 NexMed Sexual Dysfunction Drugs Description and Business Overview
  • 6.13.3 NexMed Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 6.13.4 NexMed Product Portfolio
  • 6.13.5 NexMed Recent Developments/Updates
• 6.14 S1 Biopharma
  • 6.14.1 S1 Biopharma Corporation Information
  • 6.14.2 S1 Biopharma Sexual Dysfunction Drugs Description and Business Overview
  • 6.14.3 S1 Biopharma Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 6.14.4 S1 Biopharma Product Portfolio
  • 6.14.5 S1 Biopharma Recent Developments/Updates
• 6.15 Vietstar Biomedical Research
  • 6.15.1 Vietstar Biomedical Research Corporation Information
  • 6.15.2 Vietstar Biomedical Research Sexual Dysfunction Drugs Description and Business Overview
  • 6.15.3 Vietstar Biomedical Research Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2016-2021)
  • 6.15.4 Vietstar Biomedical Research Product Portfolio
  • 6.15.5 Vietstar Biomedical Research Recent Developments/Updates

7 Sexual Dysfunction Drugs Manufacturing Cost Analysis

• 7.1 Sexual Dysfunction Drugs Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of Sexual Dysfunction Drugs
• 7.4 Sexual Dysfunction Drugs Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 Sexual Dysfunction Drugs Distributors List
• 8.3 Sexual Dysfunction Drugs Customers

9 Sexual Dysfunction Drugs Market Dynamics

• 9.1 Sexual Dysfunction Drugs Industry Trends
• 9.2 Sexual Dysfunction Drugs Growth Drivers
• 9.3 Sexual Dysfunction Drugs Market Challenges
• 9.4 Sexual Dysfunction Drugs Market Restraints

10 Global Market Forecast

• 10.1 Sexual Dysfunction Drugs Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of Sexual Dysfunction Drugs by Type (2022-2027)
  • 10.1.2 Global Forecasted Revenue of Sexual Dysfunction Drugs by Type (2022-2027)
• 10.2 Sexual Dysfunction Drugs Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Sexual Dysfunction Drugs by Application (2022-2027)
  • 10.2.2 Global Forecasted Revenue of Sexual Dysfunction Drugs by Application (2022-2027)
• 10.3 Sexual Dysfunction Drugs Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Sexual Dysfunction Drugs by Region (2022-2027)
  • 10.3.2 Global Forecasted Revenue of Sexual Dysfunction Drugs by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List